Skip to main content
. 2011 May;22(5):967–974. doi: 10.1681/ASN.2010080863

Table 1.

Clinical, biological, and arterial characteristics of the 180 patients

Parameters Mean (SD)
Age (years) 59.6 (14.2)
Gender (F/M) 47/133
Body mass index (kg/m2) 25.7 (4.7)
Hypertension, n (%) 164 (91%)
Tabacco, current n (%) 29 (16%)
Dyslipidemia, n (%) 122 (68%)
Diabetes, n (%) 25 (14%)
Previous CV event, n (%) 51 (29%)
ACEi, n (%) 103 (57%)
ARB, n (%) 110 (61%)
Dual blockade, n (%) 61 (34%)
ACEi or ARB, n (%) 152 (74%)
Calcium channel blockers, n (%) 96 (53%)
β blockers, n (%) 70 (39%)
Diuretics, n (%) 70 (39%)
Nb anti-hypertensive drugs 2.5 (1.3)
Statins, n (%) 104 (58%)
Erythropietin, n (%) 17 (9%)
Alfacalcidol, n (%) 44 (25%)
Calcium supplementation, n (%) 31 (17%)
Mean follow-up (years) 3.1 (0.3)
Slope mGFR, (ml/min per 1.73 m2 per year) −1.7 (3.7)
Dialysis during follow-up, n (%) 41 (27%)
Death, n (%) 10 (6%)
Brachial BP
    systolic BP (mmHg) 134 (22)
    mean BP (mmHg) 94 (13)
    diastolic BP (mmHg) 74 (10)
Heart rate (bpm) 65 (11)
Biological parameters
    measured GFR (ml/min per 1.73 m2) 32 (16)
    creatinine (μmol/L) 224 (113)
    UACR (mg/mmol) 19.8 (70)a
    HbA1C (%) 5.6 (1.08)
    total cholesterol (mmol/L) 4.8 (1.13)
    HDL cholesterol (mmol/L) 1.15 (0.4)
    LDL cholesterol (mmol/L) 2.9 (1.02)
    triglycerides (mmol/L) 1.5 (0.84)

ACEi, angiotensinogen converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CV, cardiovascular; UACR, urinary albumin creatinine ratio.

aMedian (interquartile range).